YouthPrEP: Youth-focused Strategies to Promote Adherence to Pre-exposure Prophylaxis Among Youth At-risk for HIV in Thailand

Sponsor
Chulalongkorn University (Other)
Overall Status
Completed
CT.gov ID
NCT03778892
Collaborator
Thai Red Cross AIDS Research Centre (Other), International AIDS Society (Other)
200
1
2
21.5
9.3

Study Details

Study Description

Brief Summary

A randomized controlled clinical trial looking at the effect of use of a mobile phone application in addition to standard care compared to standard care alone at a youth-friendly clinic in young men who have sex with men and transgender women aged between 15-19 years at risk of HIV on PrEP adherence.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: 'Project Raincoat' Mobile Phone Application
N/A

Detailed Description

OBJECTIVES

Primary Objectives:

To study PrEP adherence in adolescent MSM who are at high risk of HIV acquisition.

Secondary Objectives:

To study

  1. Rates of HIV infection

  2. Rates of sexually transmitted infections (STIs)

  3. Sexual risk taking behaviours In adolescent MSM who are at high risk of HIV infection.

HYPOTHESES:
  1. The investigators hypothesize that youth-focused interventions will produce superior adherence to PrEP from 50% with standard interventions to 70% with youth focused interventions.

  2. The investigators hypothesize that adherence to PrEP varies by the level of risk behavior one perceives. Participants who take higher risk behaviors will be more likely to adhere to PrEP than participants who have lower risk behaviors. STIs are expected to be more common among participants with higher levels of adherence if they are participants who have higher risk behaviors.

RESEARCH DESIGN:

Randomised control trial, behavioural intervention

RESEARCH METHODOLOGY

  1. Study population Volunteers aged 15 to under 20 years at high risk of HIV infection receiving PrEP under the 'Princess PrEP' project

  2. Inclusion Criteria

  • Adolescent men who have sex with men

  • At high risk of HIV infection (have at least one of the following)

  • More than 1 sexual partner in the last 6 months

  • Irregular condom use during sexual intercourse

  • HIV positive sexual partner

  • Age 15 to under 20 years old

  • A desire to take PrEP to prevent HIV infection

  • Tested HIV negative within 1 month of enrolment

  • Able to provide written consent or assent to take part in the clinical trial

  1. Exclusion criteria Signs or symptoms of acute retroviral syndrome that cannot be confirmed to be due to alternate causes, including unremitting fevers, headaches, myalgia, fatigue, and lymphadenopathy

  2. Study recruitment

  • Eligible persons presenting to the Thai Red Cross Anonymous Clinic (TRCARC) or its affiliated community based organizations (Rainbow Sky Association Thailand (RSAT) Ramkamhaeng, Sex Workers in Action Group (SWING) Bangkok will be asked by counsellors on their interest to join the study.

  • Number of participants to be studied: 200

  1. Informed consent process/ informed assent The research doctor will explain to potential participants about the purposes of the study and allow them to ask any questions they may have on it, and will be given time to make their decision. If a participant chooses to join the study, they will be asked for their written consent/assent and a copy of the informed consent/assent form given to them.
  • Participants aged between 15 and 18 will be asked for assent. As this is a study on sexual health where disease prevention is of utmost concern, parental consent will not be asked for.

  • Participants aged 18 to 19 will be asked for consent.

  1. Study procedure After informed consent or assent, all youth will commence once daily TFV/FTC 200/300mg. Volunteers will be randomized into arms 1 (standard intervention) or 2 (novel intervention strategy). Both groups will receive youth-focused counselling by trained counsellors and have access to an adolescent-friendly sexual health promotion website and social media page where they can get in contact with counsellors, doctors, fellow adolescents and function as a platform through which they can learn about good sexual health practices. Adolescents in arm 2 (novel intervention strategy) will also receive access to a mobile phone application.

Youth-focused counselling Counsellors will provide counselling that is friendly, non-judgmental and utilize motivational interviewing techniques where sessions are more collaborative rather than didactic.

Mobile Phone Application

  • Password protection will ensure user privacy

  • Will allow users to input weekly data on their:

  • Sexual risk e.g. no sexual activity, sex with condoms, sex without condoms

  • PrEP use e.g. whether or not participants take their PrEP

  • The application will calculate a percentage of protection users have based on their data entry

  • Points can be accumulated for application use, data input to the application, for attending appointments and also for normal STI and HIV screening results. Points can be redeemed for cash

  • The overall goal of the application is to increase participant awareness of self-risk and motivation to protect themselves against HIV and STI infection

Participants will be followed up at months 1, 3 and 6. At each visit, participants will complete a questionnaire on drug adherence and sexual health risk behaviours.

STI testing will be done as an indirect marker of condom use at visits 1 and 6. This will involve blood testing for syphilis serology and nucleic acid amplification testing for gonorrhea, and chlamydia on swab samples.

HIV testing will be done at all visits. TFV-DP DBS will be done at months 1, 3 and 6 to look at correlation of self-reported and actual measured PrEP compliance.

Drug Concentrations will be measured using the TFV-DP DBS at the Program for HIV Prevention and Treatment (PHPT), Chiang Mai. TFV-DP DBS levels ≥ 700 fmol/punch will be taken as adherence

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
half of study participants will receive the interventionhalf of study participants will receive the intervention
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Youth-focused Strategies to Promote Adherence to Pre-exposure Prophylaxis Among Youth At-risk for HIV in Thailand
Actual Study Start Date :
Mar 1, 2018
Actual Primary Completion Date :
Dec 15, 2019
Actual Study Completion Date :
Dec 15, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Novel Intervention

Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services

Behavioral: 'Project Raincoat' Mobile Phone Application
Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.

No Intervention: Standard Intervention

Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services

Outcome Measures

Primary Outcome Measures

  1. PrEP Adherence [Weekly self-reported adherence for a period of 6 months following randomization]

    Self-Reported Adherence

  2. PrEP Adherence at 3 months [Measured at month 3 (measure of 17 day half life of TDF-DP)]

    Measured Serum TDF-DP Level (from dried blood spots)

  3. PrEP Adherence at 6 months [Measured at month 6 (measure of 17 day half life of TDF-DP)]

    Measured Serum TDF-DP Level (from dried blood spots)

Secondary Outcome Measures

  1. HIV infection rates [duration of study (6 months)]

    seroconversion rates whilst on PrEP during study

  2. Rates of Urethral Neisseria gonorrhea [duration of study (6 months)]

    Rates of Urethral Neisseria gonorrhea via Nucleic Acid Amplification Screening (NAAT) urine testing

  3. Behaviour Risk-Taking [duration of study (6 months)]

    Composite calculated score of risk taking based on self-reported condom use, PrEP tablets taking, number of sexual partners in preceding one month. Scores will equate to risk levels of low, medium, high and very high.

  4. Rates of Anal Neisseria gonorrhea [duration of study (6 months)]

    Rates of Anal Neisseria gonorrhea via Nucleic Acid Amplification Screening (NAAT) from anal swab samples

  5. Rates of Urethral Chlamydia trachomatis [duration of study (6 months)]

    Rates of Urethral Chlamydia trachomatis via Nucleic Acid Amplification Screening (NAAT) urine testing

  6. Rates of Anal Chlamydia trachomatis [duration of study (6 months)]

    Rates of Anal Chlamydia trachomatis via Nucleic Acid Amplification Screening (NAAT) from anal swab samples

  7. Rates of Syphilis Infection [duration of study (6 months)]

    Rates of positive treponemal blood tests

  8. Rates of Hepatitis B infection [At initial project visit (month 0)]

    Rates of positive HbsAg blood tests

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 19 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adolescent men who have sex with men

  • At high risk of HIV infection (have at least one of the following)

  • More than 1 sexual partner in the last 6 months

  • Irregular condom use during sexual intercourse

  • HIV positive sexual partner

  • Age 15 to under 20 years old

  • A desire to take PrEP to prevent HIV infection

  • Tested HIV negative within 1 month of enrolment

  • Able to provide written consent or assent to take part in the clinical trial

Exclusion Criteria:
  • Signs or symptoms of acute retroviral syndrome that cannot be confirmed to be due to alternate causes, including unremitting fevers, headaches, myalgia, fatigue, and lymphadenopathy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Thai Red Cross AIDS Research Center Bangkok Thailand 10330

Sponsors and Collaborators

  • Chulalongkorn University
  • Thai Red Cross AIDS Research Centre
  • International AIDS Society

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wipaporn Natalie Songtaweesin, MD., Principal Investigator, Clinical Researcher, Chulalongkorn University
ClinicalTrials.gov Identifier:
NCT03778892
Other Study ID Numbers:
  • 2017/472-SON
First Posted:
Dec 19, 2018
Last Update Posted:
Jan 23, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wipaporn Natalie Songtaweesin, MD., Principal Investigator, Clinical Researcher, Chulalongkorn University

Study Results

No Results Posted as of Jan 23, 2020